Na+/H+ Exchanger (NHE)

Sodium/hydrogen Exchanger; Sodium-hydrogen Exchanger

Na⁺/H⁺ exchanger (sodium/hydrogen exchanger, NHE) family exchanges Na⁺ for H⁺ according to their concentration gradients, thus promotes the regulation of the stability of cytoplasmic pH and cell volume.

There are nine isoforms of NHE in humans, some NHEs function primarily on the plasma membrane, and others are present on intracellular organelles. NHE1 is expressed in the plasma membrane of virtually all tissues and plays an important role in cardiac health. NHE2 is expressed in the gastrointestinal (GI) tract and contributes to the maintenance of stomach pH and homeostasis, whereas NHE3 predominates in the GI tract and kidneys. NHE4 and NHE5 are abundant in the stomach and brain, respectively. NHE6-9 are expressed in the intracellular compartments of many organ system membranes, but of these NHE8 is the exception and expressed apically.

Na+/H+ Exchanger (NHE) Related Products (30):

By Effects:	Inhibitors (26) Antagonist (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-101840

EIPA	Inhibitor	99.73%
EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA also enhances autophagy by inhibiting Na⁺/H⁺-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.

HY-N0150

Monensin sodium		≥98.0%
Monensin (Monensin A) sodium, an orally active antibiotic, is an ionophore that mediates Na⁺/H⁺ exchange. Monensin sodium is a potent Wnt signaling inhibitor. Monensin sodium causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin sodium can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects.

HY-19693

Cariporide	Inhibitor	99.89%
Cariporide (HOE-642) is a selective Na⁺/H⁺ exchange inhibitor.

HY-101840A

EIPA hydrochloride	Antagonist	98.31%
EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na⁺/H⁺-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.

HY-15991

Tenapanor	Inhibitor	99.65%
Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor has the potential for the research of hyperphosphatemia.

HY-105064

Zoniporide	Inhibitor	99.89%
Zoniporide (CP-597396) is a potent and selective NHE-1 inhibitor with cardioprotective activity. Zoniporide inhibits ²²Na⁺ uptake by human NHE-1-expressing fibroblasts in a concentration-dependent manner (IC₅₀=14 nM). Zoniporide inhibits platelet swelling in vitro with an IC₅₀ of 0.059 μM. Zoniporide can be used in the study of cardiovascular disease.

HY-N0150R

Monensin sodium (Standard)
Monensin (sodium) (Standard) is the analytical standard of Monensin (sodium). This product is intended for research and analytical applications. Monensin (Monensin A) sodium, an orally active antibiotic, is an ionophore that mediates Na+/H+ exchange. Monensin sodium is a potent Wnt signaling inhibitor. Monensin sodium causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin sodium can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects.

HY-120623

BMS-284640	Inhibitor
BMS-284640 is a synthetic sodium hydrogen exchange isomer-1 (NHE-1) inhibitor. BMS-284640 has a more than 380-fold higher NHE-1 inhibitory activity (IC50: 9 nM) compared to cariporide (HY-19693) and is more selective for NHE-1 over NHE-2 (IC50: 1.8 μM) and NHE-5 (IC50: 3.36 μM). BMS-284640 and its analogs also exhibit enhanced oral bioavailability and prolonged plasma half-life in rats..

HY-19273

Rimeporide	Inhibitor	98.71%
Rimeporide (EMD-87580) is a potent and selective inhibitor of the Na⁺/H⁺ exchanger (NHE-1).

HY-18071

BI-9627	Inhibitor	≥99.0%
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC₅₀s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury.

HY-105064D

Zoniporide hydrochloride hydrate	Inhibitor	99.37%
Zoniporide (CP-597396) hydrochloride hydrate is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride hydrate inhibits human NHE-1 (IC₅₀=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride hydrate potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC₅₀=59 nM).

HY-106150B

Eniporide hydrochloride	Inhibitor	98.97%
Eniporide hydrochloride (EMD-96785 hydrochloride) is a potent Na⁺/H⁺ exchange inhibitor.

HY-15991A

Tenapanor hydrochloride	Inhibitor	98.71%
Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia.

HY-18071A

BI-9627 hydrochloride	Inhibitor	98.01%
BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury.

HY-139313

NHE3-IN-2	Inhibitor	98.65%
NHE3-IN-2 is a Na⁺/H⁺ exchanger-3 (NHE3) inhibitor ( patent WO2001079186A1, example 6-Chlor-4-phenyl-2-chinazolinyl-guanidin).

HY-N4302

Monensin
Monensin (Monensin A), an orally active antibiotic, is an ionophore that mediates Na⁺/H⁺ exchange. Monensin is a potent Wnt signaling inhibitor. Monensin causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects.

HY-105064B

Zoniporide hydrochloride	Inhibitor
Zoniporide (CP-597396) hydrochloride is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride inhibits human NHE-1 (IC₅₀=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC₅₀=59 nM).

HY-105064C

Zoniporide dihydrochloride	Inhibitor
Zoniporide dihydrochloride (CP-597396 dihydrochloride) is a potent and selective inhibitor of highly water-soluble sodium hydrogen exchange type 1 (NHE-1). Zoniporide dihydrochloride inhibits NHE1 dependent 22Na⁺ uptake in vitro with an IC₅₀ of 14 nM. Zoniporide has antitumor activity.

HY-122525A

Sabiporide hydrochloride	Inhibitor
Sabiporide hydrochloride is a NHE-1 inhibitor (K_i: 50 nM). Sabiporide hydrochloride has cardioprotective and neuroprotective effects. Sabiporide hydrochloride inhibits glutamate- or NMDA-induced neuronal cell death.

HY-100325

NHE3-IN-1	Inhibitor	98.05%
NHE3-IN-1 is a sodium/proton exchanger type 3 (NHE-3) inhibitor extracted from patent WO 2011019784 A1.

Name
Email *

	Sorry, but the email address you supplied was invalid.